Achieve Life Sciences Inc is trading at $5.09 (-5.04%) today. The decline comes as the Prescription Drug User Fee Act (PDUFA) date of June 20, 2026, for its cytisinicline New Drug Application (NDA) nears. - The company has previously indicated an expectation to receive a Complete Response Letter (CRL) from the FDA on or before the PDUFA date due to manufacturing issues with a former third-party supplier. - Achieve Life Sciences plans to resubmit the NDA in the fourth quarter of 2026, naming Adare Pharma Solutions as its new primary manufacturing partner.